347: More HHS upheaval, 23andMe's bankruptcy, and AI for cancer survival
The Readout Loud
00:00
Navigating 23andMe's Challenges
This chapter explores the difficulties faced by 23andMe as it attempts to pivot from consumer DNA testing to the pharmaceutical sector. It features insights from investors and co-founders, addressing concerns about the company's leadership, data security, and the broader implications for drug development amid ongoing struggles.
Transcript
Play full episode
